Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Apr 01 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

The press release highlights that the vaccine's safety and efficacy data were peer-reviewed and confirms the trial's compliance with global standards. Dr. Sharvil Patel, the Managing Director, expressed satisfaction with the publication, emphasizing adherence to stringent clinical trial practices.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases